Innate Pharma announces that the first patient has been treated in the phase 2 dose-extension study conducted by Sanofi, evaluating SAR443579 / IPH6101 as a monotherapy to treat various hematological cancers with unmet medical needs.

The pharmaceutical company specifies that the cancers studied include relapsed/refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome.

This progress in the trial has triggered a milestone payment of four million euros from Sanofi to Innate. SAR443579, the result of a collaboration between the two groups, has been granted Fast Track status by the US FDA for the treatment of AML.

Copyright (c) 2024 All rights reserved.